ATE322547T1 - Adenovirale vektoren für die behandlung der hämophilie - Google Patents
Adenovirale vektoren für die behandlung der hämophilieInfo
- Publication number
- ATE322547T1 ATE322547T1 AT94919977T AT94919977T ATE322547T1 AT E322547 T1 ATE322547 T1 AT E322547T1 AT 94919977 T AT94919977 T AT 94919977T AT 94919977 T AT94919977 T AT 94919977T AT E322547 T1 ATE322547 T1 AT E322547T1
- Authority
- AT
- Austria
- Prior art keywords
- hemophilia
- treatment
- adenoviral vectors
- factor
- vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 208000031220 Hemophilia Diseases 0.000 title abstract 2
- 208000009292 Hemophilia A Diseases 0.000 title abstract 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003114 blood coagulation factor Substances 0.000 abstract 2
- 210000003494 hepatocyte Anatomy 0.000 abstract 2
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- -1 for example Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7492093A | 1993-06-10 | 1993-06-10 | |
| US21833594A | 1994-03-25 | 1994-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322547T1 true ATE322547T1 (de) | 2006-04-15 |
Family
ID=26756213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94919977T ATE322547T1 (de) | 1993-06-10 | 1994-04-13 | Adenovirale vektoren für die behandlung der hämophilie |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5935935A (de) |
| EP (1) | EP0710288B1 (de) |
| JP (1) | JPH08511423A (de) |
| AT (1) | ATE322547T1 (de) |
| CA (1) | CA2162497A1 (de) |
| DE (1) | DE69434689D1 (de) |
| WO (1) | WO1994029471A1 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP0673431A1 (de) * | 1992-12-03 | 1995-09-27 | Genzyme Corporation | GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses) |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| WO1994029471A1 (en) * | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
| CA2206683A1 (en) * | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
| US6531455B1 (en) | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
| DE19512142A1 (de) * | 1995-03-31 | 1996-10-02 | Immuno Ag | Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält |
| DE19620687A1 (de) * | 1996-05-22 | 1997-11-27 | Centeon Pharma Gmbh | Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo |
| WO1997045550A2 (en) * | 1996-05-31 | 1997-12-04 | Baxter International Inc. | Mini-adenoviral vector |
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| WO1998054345A1 (en) * | 1997-05-30 | 1998-12-03 | Baxter International Inc. | Mini-adenoviral vector |
| FR2763959A1 (fr) * | 1997-06-02 | 1998-12-04 | Transgene Sa | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6200560B1 (en) * | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6221349B1 (en) * | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6410013B1 (en) * | 1999-01-25 | 2002-06-25 | Musc Foundation For Research Development | Viral vectors for use in monitoring HIV drug resistance |
| AU780854B2 (en) * | 1999-02-19 | 2005-04-21 | Octagene Gmbh | Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| EP1048726B1 (de) * | 1999-04-27 | 2006-07-26 | Négrier, Claude | Modifizierte Faktor VIII cDNA |
| EP1048736A1 (de) | 1999-04-27 | 2000-11-02 | Aventis Behring Gesellschaft mit beschränkter Haftung | DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors |
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| JP2003511082A (ja) * | 1999-10-12 | 2003-03-25 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 第viii因子をコードするアデノ随伴ウィルスベクターとその使用法 |
| EP1261379A2 (de) * | 2000-02-17 | 2002-12-04 | Genzyme Corporation | Lungentransfektion als genverabreichungsmethode |
| DK1266006T3 (da) * | 2000-03-22 | 2006-01-16 | Octagene Gmbh | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier |
| DE10020125A1 (de) * | 2000-04-18 | 2001-10-25 | Friedrich Schiller Uni Jena Bu | Agens für den postoperativen Einsatz nach Entfernung von Knochentumoren |
| AU6814901A (en) * | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| CN1148228C (zh) * | 2000-08-30 | 2004-05-05 | 夏家辉 | 治疗血友病b的基因药物及其制备方法 |
| WO2002040544A2 (en) * | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| ATE541937T1 (de) * | 2001-04-06 | 2012-02-15 | Univ Chicago | Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| AU2002256274A1 (en) * | 2001-04-18 | 2002-11-05 | Genstar Therapeutics Corp. | Minimal adenoviral vectors for immunization |
| WO2002097050A2 (en) | 2001-05-31 | 2002-12-05 | Novartis Ag | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| DE60230456D1 (de) | 2001-10-05 | 2009-01-29 | Expression Therapeutics Llc | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren |
| EP1516055A4 (de) * | 2002-01-24 | 2007-08-08 | Scripps Research Inst | Faserschaftmodifikationen für effizientes zielen |
| EP1424344A1 (de) * | 2002-11-29 | 2004-06-02 | Aventis Behring Gesellschaft mit beschränkter Haftung | Modifizierte cDNA des Factors VIII und Derivate davon |
| EP1454916A1 (de) * | 2002-11-29 | 2004-09-08 | ZLB Behring GmbH | Modifizierte cDNA des Factors VIII und Derivate davon |
| JP2004277355A (ja) * | 2003-03-17 | 2004-10-07 | Beacle Inc | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
| CA2519680A1 (en) | 2003-03-28 | 2004-11-18 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| WO2005017149A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| PL1750733T3 (pl) * | 2004-05-03 | 2014-05-30 | Univ Emory | Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B |
| ES2436741T3 (es) | 2004-09-22 | 2014-01-07 | St. Jude Children's Research Hospital | Expresión mejorada de Factor IX en vectores de terapia génica |
| US8234238B2 (en) * | 2005-03-04 | 2012-07-31 | Maxsp Corporation | Computer hardware and software diagnostic and report system |
| RU2489486C2 (ru) | 2006-06-20 | 2013-08-10 | Трансжене С.А. | Процесс получения поксвирусов и композиции поксвирусов |
| KR101229418B1 (ko) * | 2007-06-15 | 2013-02-05 | 재단법인 목암생명공학연구소 | 활성형 재조합 혈액응고 9인자의 대량생산 방법 |
| EP2201953A4 (de) * | 2007-08-27 | 2011-08-03 | Univ Nagoya Nat Univ Corp | Verwendung von ribavirin bei blutgerinnungsstörungen |
| TW201920257A (zh) * | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| WO2010025410A2 (en) * | 2008-08-28 | 2010-03-04 | Salutria Pharmaceuticals, Llc | Screening method for identifying patients at risk of adverse hepatologic events |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| AU2010275764A1 (en) | 2009-07-21 | 2012-03-15 | Transgene Sa | Enzymatic composition for the digestion of chicken embryos |
| WO2011095604A1 (en) | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| BR112013011041B1 (pt) * | 2010-11-05 | 2021-05-25 | Baxalta GmbH | variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
| KR20210074395A (ko) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약 |
| SG10201604810UA (en) * | 2012-02-07 | 2016-08-30 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| JP2017522895A (ja) | 2014-07-31 | 2017-08-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ | 哺乳類rpe65の高イソメロヒドロラーゼ活性突然変異体 |
| WO2016070166A2 (en) * | 2014-11-02 | 2016-05-06 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| GB201420139D0 (en) * | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
| TWI759261B (zh) | 2015-02-27 | 2022-04-01 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
| CN108884145B (zh) | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
| KR102404550B1 (ko) | 2015-11-13 | 2022-05-31 | 다케다 야쿠힌 고교 가부시키가이샤 | A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터 |
| EP3394098A4 (de) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin-antikörper und verfahren zur verwendung |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| EP3620531A4 (de) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen |
| TWI753168B (zh) | 2017-05-22 | 2022-01-21 | 日商武田藥品工業股份有限公司 | 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體 |
| JP7119009B2 (ja) * | 2017-05-31 | 2022-08-16 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 最適化されたヒト凝固第ix因子遺伝子発現カセットおよびそれらの使用 |
| US12091675B2 (en) | 2018-07-16 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression |
| US11260936B2 (en) | 2018-07-31 | 2022-03-01 | Planet Rider, Llc | Gearless power conversion system employing two electric machines |
| TWI851647B (zh) | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| WO2025059113A1 (en) | 2023-09-12 | 2025-03-20 | The Board Of Regents Of The University Of Oklahoma | Treatments for enhancing immune response to clostridioides difficile infections |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000560A1 (en) * | 1982-08-04 | 1984-02-16 | Nat Res Dev | Molecular cloning of the gene for human anti-haemophilic factor ix |
| US4757006A (en) * | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4716117A (en) * | 1984-10-26 | 1987-12-29 | Chiron Corporation | Monoclonal antibodies to factor VIIIC |
| US5045455A (en) * | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
| US5004804A (en) * | 1984-01-12 | 1991-04-02 | Nordisk Gentofte | Method and composition for preparation of factor VIIIC |
| AU587989B2 (en) * | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
| MX9203440A (es) * | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| US5149639A (en) * | 1986-03-24 | 1992-09-22 | Abbott Laboratories | Biologically pure cultures of streptomyces and use thereof in macrolide antibiotic production |
| US5032511A (en) * | 1987-03-31 | 1991-07-16 | Mitsubishi Kasei Corporation | DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens |
| US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
| US4994371A (en) * | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) * | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| EP0530365A1 (de) * | 1991-01-29 | 1993-03-10 | Teijin Limited | Vektor zur expression menschlichen proteins-c |
| ATE237694T1 (de) * | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| EP0673431A1 (de) * | 1992-12-03 | 1995-09-27 | Genzyme Corporation | GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses) |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| WO1994029471A1 (en) * | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
| FR2707664B1 (fr) * | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| CA2144040A1 (fr) * | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| FR2763959A1 (fr) | 1997-06-02 | 1998-12-04 | Transgene Sa | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage |
-
1994
- 1994-04-13 WO PCT/US1994/004075 patent/WO1994029471A1/en not_active Ceased
- 1994-04-13 DE DE69434689T patent/DE69434689D1/de not_active Expired - Fee Related
- 1994-04-13 EP EP94919977A patent/EP0710288B1/de not_active Expired - Lifetime
- 1994-04-13 AT AT94919977T patent/ATE322547T1/de not_active IP Right Cessation
- 1994-04-13 CA CA002162497A patent/CA2162497A1/en not_active Abandoned
- 1994-04-13 JP JP7501744A patent/JPH08511423A/ja active Pending
-
1995
- 1995-06-07 US US08/484,891 patent/US5935935A/en not_active Expired - Fee Related
-
1998
- 1998-09-10 US US09/150,811 patent/US6649375B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5935935A (en) | 1999-08-10 |
| DE69434689D1 (de) | 2006-05-18 |
| US6649375B2 (en) | 2003-11-18 |
| CA2162497A1 (en) | 1994-12-22 |
| EP0710288A1 (de) | 1996-05-08 |
| EP0710288B1 (de) | 2006-04-05 |
| US20020064812A1 (en) | 2002-05-30 |
| EP0710288A4 (de) | 1998-02-04 |
| JPH08511423A (ja) | 1996-12-03 |
| WO1994029471A1 (en) | 1994-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434689D1 (de) | Adenovirale vektoren für die behandlung der hämophilie | |
| ATE486614T1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| DE69731611D1 (de) | Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor | |
| FI962990A0 (fi) | Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä | |
| ATE110412T1 (de) | Translation von mrna. | |
| TR28128A (tr) | Deterjan bilesimlerinde kir salma maddeleri olarak kullanima müsait sülfone poli-etoksi/propoksi uc-baslikli ester oligomerleri. | |
| MX157180A (es) | Mejoras en una composicion detergente liquida | |
| DE60015070D1 (de) | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache | |
| DE59410380D1 (de) | Endosomolytisch wirksame partikel | |
| BG102612A (en) | Complementary adenoviral vector systems and cellular lines | |
| FR2710063B1 (fr) | 3-Aryl-benzofurannones, utilisées en tant que stabilisants, compositions les contenant, et leur utilisation. | |
| EA199800667A1 (ru) | Новые фенантридины | |
| FR2712286B1 (fr) | Nouveaux N-mercaptoalkyl alcanediamines et leur utilisation. | |
| DE3870508D1 (de) | Zusammensetzung zur behandlung des haares. | |
| ATE98939T1 (de) | Stabilisierung von konzentrierten wasserstoffperoxydloesungen. | |
| DE69934998D1 (de) | Antisense modulation der expression von integrin alpha 4 | |
| FI961666A7 (fi) | Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria | |
| ATE296312T1 (de) | Metalkomplexbildner | |
| SE8902532L (sv) | Bestaemning av plasmaproteiner | |
| ATE196083T1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| DE69840948D1 (de) | Invertierte terminale repeats von aav, die für die transkription aktiviert sind, zur verwendung in rekombinanten aav-vektoren | |
| DE50108409D1 (de) | Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens | |
| DE69014298D1 (de) | Stabilisierung von wasserstoffperoxydlösungen. | |
| FR2735026B1 (fr) | Composition capillaire comprenant un extrait de myrte, son procede de preparation et son utilisation notamment pour un traitement antipelliculaire. | |
| ATE172470T1 (de) | Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |